Related Experiment Video
Updated: Dec 6, 2025
Quantitative Immunohistochemistry of the Cellular Microenvironment in Patient Glioblastoma Resections
Published on: July 31, 2017
Surgical Site Infections after glioblastoma surgery: results of a multicentric retrospective study
Henri Salle1,2, Elise Deluche3, Elodie Couvé-Deacon4
1Neurochirurgie, CHU de Limoges, Limoges, France. henrisalle1@gmail.com.
Background:
The effects of surgical site infections (SSI) after glioblastoma surgery on patient outcomes are understudied. The aim of this retrospective multicenter study was to evaluate the impact of SSI on the survival of glioblastoma patients.
Methods:
Data from SSI cases after glioblastoma surgeries between 2009 and 2016 were collected from 14 French neurosurgical centers. Collected data included patient demographics, previous medical history, risk factors, details of the surgical procedure, radiotherapy/chemotherapy, infection characteristics, and infection management. Similar data were collected from gender- and age-paired control individuals.
Results:
We used the medical records of 77 SSI patients and 58 control individuals. 13 were excluded. Our analyses included data from 64 SSI cases and 58 non-infected glioblastoma patients. Infections occurred after surgery for primary tumors in 38 cases (group I) and after surgery for a recurrent tumor in 26 cases (group II). Median survival was 381, 633, and 547 days in patients of group I, group II, and the control group, respectively. Patients in group I had significantly shorter survival compared to the other two groups (p < 0.05). The one-year survival rate of patients who developed infections after surgery for primary tumors was 50%. Additionally, we found that SSIs led to postoperative treatment discontinuation in 30% of the patients.
Discussion:
Our findings highlighted the severity of SSIs after glioblastoma surgery, as they significantly affect patient survival. The establishment of preventive measures, as well as guidelines for the management of SSIs, is of high clinical importance.
Insights
Surgical site infections (SSI) after glioblastoma surgery significantly reduce patient survival, particularly after primary tumor operations. Implementing preventive measures and management guidelines for SSI is crucial for improving outcomes in glioblastoma patients.
Area of Science:
- Neurosurgery
- Oncology
- Infectious Diseases
Background:
- Surgical site infections (SSI) following glioblastoma surgery are an understudied complication.
- The impact of SSI on glioblastoma patient survival requires further investigation.
Purpose of the Study:
- To evaluate the impact of SSI on the survival of glioblastoma patients.
- To analyze survival data in relation to primary vs. recurrent tumor surgery and SSI occurrence.
Main Methods:
- Retrospective multicenter study involving 14 French neurosurgical centers.
- Collected data on 64 SSI cases and 58 controls from glioblastoma surgeries (2009-2016).
- Analyzed patient demographics, surgical details, treatment, and infection characteristics.
Main Results:
- Median survival was significantly shorter for patients with SSI after primary glioblastoma surgery (381 days) compared to recurrent surgery (633 days) and controls (547 days).
- One-year survival rate for primary tumor SSI was 50%.
- SSI led to postoperative treatment discontinuation in 30% of patients.
Conclusions:
- Surgical site infections pose a significant threat to glioblastoma patient survival.
- There is a critical need for enhanced SSI prevention strategies and management guidelines in glioblastoma care.
